Biomarin Pharmaceutical (BMRN) earnings, Nov 2, 2026: EPS +244%, stock −3.1%
In brief
Biomarin Pharmaceutical reported on Nov 2, 2026. Earnings per share changed +244% year over year, 566.2% above the estimate; revenue +32%. The stock opened with a −7.6% gap and closed the day −3.1% (Nov 3, 2026). The stock is now 20.9% below its 52-week high, +6.3% over 12 months. Next report: Feb 24, 2027.
EPS vs estimate+566.2%
EPS, YoY+244%
Revenue, YoY+32%
Gap · day−7.6% · −3.1%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Aug 6, 2026 | +5.5% | +3.8% |
| Nov 2, 2026 | −7.6% | −3.1% |
Next-quarter estimates, ratings and the BMRN chart are in the terminal.
Open the terminalFAQ
When is Biomarin Pharmaceutical's next earnings report?
Feb 24, 2027. The date comes from daily data and is corrected if the company moves it.
How did Biomarin Pharmaceutical stock react to the report?
Opening gap −7.6%, day's result −3.1%.
Did Biomarin Pharmaceutical's earnings grow?
Earnings per share rose 244% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.